<!DOCTYPE html>
<!-- Generated by pkgdown: do not edit by hand --><html lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta charset="utf-8"><meta http-equiv="X-UA-Compatible" content="IE=edge"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><meta name="description" content="The function optimal_normal of the drugdevelopR
package enables planning of phase II/III drug development programs with
optimal sample size allocation and go/no-go decision rules for normally
distributed endpoints. The treatment effect is measured by the standardized
difference in means. The assumed true treatment effects can be assumed to be
fixed or modelled by a prior distribution. The R Shiny application
prior visualizes the prior
distributions used in this package. Fast computing is enabled by parallel
programming."><title>Optimal phase II/III drug development planning with normally distributed endpoint — optimal_normal • drugdevelopR</title><script src="../deps/jquery-3.6.0/jquery-3.6.0.min.js"></script><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><link href="../deps/bootstrap-5.3.1/bootstrap.min.css" rel="stylesheet"><script src="../deps/bootstrap-5.3.1/bootstrap.bundle.min.js"></script><!-- Font Awesome icons --><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/all.min.css" integrity="sha256-mmgLkCYLUQbXn0B1SRqzHar6dCnv9oZFPEC1g1cwlkk=" crossorigin="anonymous"><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/v4-shims.min.css" integrity="sha256-wZjR52fzng1pJHwx4aV2AO3yyTOXrcDW7jBpJtTwVxw=" crossorigin="anonymous"><!-- bootstrap-toc --><script src="https://cdn.jsdelivr.net/gh/afeld/bootstrap-toc@v1.0.1/dist/bootstrap-toc.min.js" integrity="sha256-4veVQbu7//Lk5TSmc7YV48MxtMy98e26cf5MrgZYnwo=" crossorigin="anonymous"></script><!-- headroom.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/headroom.min.js" integrity="sha256-AsUX4SJE1+yuDu5+mAVzJbuYNPHj/WroHuZ8Ir/CkE0=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/jQuery.headroom.min.js" integrity="sha256-ZX/yNShbjqsohH1k95liqY9Gd8uOiE1S4vZc+9KQ1K4=" crossorigin="anonymous"></script><!-- clipboard.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/2.0.6/clipboard.min.js" integrity="sha256-inc5kl9MA1hkeYUt+EC3BhlIgyp/2jDIyBLS6k3UxPI=" crossorigin="anonymous"></script><!-- search --><script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/6.4.6/fuse.js" integrity="sha512-zv6Ywkjyktsohkbp9bb45V6tEMoWhzFzXis+LrMehmJZZSys19Yxf1dopHx7WzIKxr5tK2dVcYmaCk2uqdjF4A==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/autocomplete.js/0.38.0/autocomplete.jquery.min.js" integrity="sha512-GU9ayf+66Xx2TmpxqJpliWbT5PiGYxpaG8rfnBEk1LL8l1KGkRShhngwdXK1UgqhAzWpZHSiYPc09/NwDQIGyg==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/mark.min.js" integrity="sha512-5CYOlHXGh6QpOFA/TeTylKLWfB3ftPsde7AnmhuitiTX4K5SqCLBeKro6sPS8ilsz1Q4NRx3v8Ko2IBiszzdww==" crossorigin="anonymous"></script><!-- pkgdown --><script src="../pkgdown.js"></script><meta property="og:title" content="Optimal phase II/III drug development planning with normally distributed endpoint — optimal_normal"><meta property="og:description" content="The function optimal_normal of the drugdevelopR
package enables planning of phase II/III drug development programs with
optimal sample size allocation and go/no-go decision rules for normally
distributed endpoints. The treatment effect is measured by the standardized
difference in means. The assumed true treatment effects can be assumed to be
fixed or modelled by a prior distribution. The R Shiny application
prior visualizes the prior
distributions used in this package. Fast computing is enabled by parallel
programming."><!-- mathjax --><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js" integrity="sha256-nvJJv9wWKEm88qvoQl9ekL2J+k/RWIsaSScxxlsrv8k=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/config/TeX-AMS-MML_HTMLorMML.js" integrity="sha256-84DKXVJXs0/F8OTMzX4UR909+jtl4G7SPypPavF+GfA=" crossorigin="anonymous"></script><!--[if lt IE 9]>
<script src="https://oss.maxcdn.com/html5shiv/3.7.3/html5shiv.min.js"></script>
<script src="https://oss.maxcdn.com/respond/1.4.2/respond.min.js"></script>
<![endif]--></head><body>
    <a href="#main" class="visually-hidden-focusable">Skip to contents</a>
    

    <nav class="navbar fixed-top navbar-light navbar-expand-lg bg-light"><div class="container">
    
    <a class="navbar-brand me-2" href="../index.html">drugdevelopR</a>

    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">1.0.0</small>

    
    <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
      <span class="navbar-toggler-icon"></span>
    </button>

    <div id="navbar" class="collapse navbar-collapse ms-3">
      <ul class="navbar-nav me-auto"><li class="active nav-item">
  <a class="nav-link" href="../reference/index.html">Reference</a>
</li>
<li class="nav-item dropdown">
  <a href="#" class="nav-link dropdown-toggle" data-bs-toggle="dropdown" role="button" aria-expanded="false" aria-haspopup="true" id="dropdown-articles">Articles</a>
  <div class="dropdown-menu" aria-labelledby="dropdown-articles">
    <a class="dropdown-item" href="../articles/Introduction-to-drugdevelopR.html">Introduction to planning phase II and phase III trials with drugdevelopR</a>
    <a class="dropdown-item" href="../articles/Package_validation.html">Package validation</a>
    <div class="dropdown-divider"></div>
    <a class="dropdown-item" href="../articles/index.html">More articles...</a>
  </div>
</li>
<li class="nav-item">
  <a class="nav-link" href="../news/index.html">Changelog</a>
</li>
      </ul><form class="form-inline my-2 my-lg-0" role="search">
        <input type="search" class="form-control me-sm-2" aria-label="Toggle navigation" name="search-input" data-search-index="../search.json" id="search-input" placeholder="Search for" autocomplete="off"></form>

      <ul class="navbar-nav"><li class="nav-item">
  <a class="external-link nav-link" href="https://github.com/Sterniii3/drugdevelopR/" aria-label="github">
    <span class="fab fa fab fa-github fa-lg"></span>
     
  </a>
</li>
      </ul></div>

    
  </div>
</nav><div class="container template-reference-topic">
<div class="row">
  <main id="main" class="col-md-9"><div class="page-header">
      <img src="" class="logo" alt=""><h1>Optimal phase II/III drug development planning with normally distributed endpoint</h1>
      <small class="dont-index">Source: <a href="https://github.com/Sterniii3/drugdevelopR/blob/HEAD/R/optimal_normal.R" class="external-link"><code>R/optimal_normal.R</code></a></small>
      <div class="d-none name"><code>optimal_normal.Rd</code></div>
    </div>

    <div class="ref-description section level2">
    <p>The function <code>optimal_normal</code> of the <code><a href="drugdevelopR.html">drugdevelopR</a></code>
package enables planning of phase II/III drug development programs with
optimal sample size allocation and go/no-go decision rules for normally
distributed endpoints. The treatment effect is measured by the standardized
difference in means. The assumed true treatment effects can be assumed to be
fixed or modelled by a prior distribution. The R Shiny application
<a href="https://web.imbi.uni-heidelberg.de/prior/" class="external-link">prior</a> visualizes the prior
distributions used in this package. Fast computing is enabled by parallel
programming.</p>
    </div>

    <div class="section level2">
    <h2 id="ref-usage">Usage<a class="anchor" aria-label="anchor" href="#ref-usage"></a></h2>
    <div class="sourceCode"><pre class="sourceCode r"><code><span><span class="fu">optimal_normal</span><span class="op">(</span></span>
<span>  <span class="va">w</span>,</span>
<span>  <span class="va">Delta1</span>,</span>
<span>  <span class="va">Delta2</span>,</span>
<span>  <span class="va">in1</span>,</span>
<span>  <span class="va">in2</span>,</span>
<span>  <span class="va">a</span>,</span>
<span>  <span class="va">b</span>,</span>
<span>  <span class="va">n2min</span>,</span>
<span>  <span class="va">n2max</span>,</span>
<span>  <span class="va">stepn2</span>,</span>
<span>  <span class="va">kappamin</span>,</span>
<span>  <span class="va">kappamax</span>,</span>
<span>  <span class="va">stepkappa</span>,</span>
<span>  <span class="va">alpha</span>,</span>
<span>  <span class="va">beta</span>,</span>
<span>  <span class="va">c2</span>,</span>
<span>  <span class="va">c3</span>,</span>
<span>  <span class="va">c02</span>,</span>
<span>  <span class="va">c03</span>,</span>
<span>  K <span class="op">=</span> <span class="cn">Inf</span>,</span>
<span>  N <span class="op">=</span> <span class="cn">Inf</span>,</span>
<span>  S <span class="op">=</span> <span class="op">-</span><span class="cn">Inf</span>,</span>
<span>  steps1 <span class="op">=</span> <span class="fl">0</span>,</span>
<span>  stepm1 <span class="op">=</span> <span class="fl">0.5</span>,</span>
<span>  stepl1 <span class="op">=</span> <span class="fl">0.8</span>,</span>
<span>  <span class="va">b1</span>,</span>
<span>  <span class="va">b2</span>,</span>
<span>  <span class="va">b3</span>,</span>
<span>  gamma <span class="op">=</span> <span class="fl">0</span>,</span>
<span>  fixed <span class="op">=</span> <span class="cn">FALSE</span>,</span>
<span>  skipII <span class="op">=</span> <span class="cn">FALSE</span>,</span>
<span>  num_cl <span class="op">=</span> <span class="fl">1</span></span>
<span><span class="op">)</span></span></code></pre></div>
    </div>

    <div class="section level2">
    <h2 id="arguments">Arguments<a class="anchor" aria-label="anchor" href="#arguments"></a></h2>
    <dl><dt>w</dt>
<dd><p>weight for
<a href="https://web.imbi.uni-heidelberg.de/prior/" class="external-link">mixture prior distribution</a></p></dd>


<dt>Delta1</dt>
<dd><p>assumed true prior treatment effect measured as the
standardized difference in means, see
<a href="https://web.imbi.uni-heidelberg.de/prior/" class="external-link">here</a> for details</p></dd>


<dt>Delta2</dt>
<dd><p>assumed true prior treatment effect measured as the
standardized difference in means, see
<a href="https://web.imbi.uni-heidelberg.de/prior/" class="external-link">here</a> for details</p></dd>


<dt>in1</dt>
<dd><p>amount of information for <code>Delta1</code> in terms of sample size, see
<a href="https://web.imbi.uni-heidelberg.de/prior/" class="external-link">here</a>
for details</p></dd>


<dt>in2</dt>
<dd><p>amount of information for <code>Delta2</code> in terms of sample size, see
<a href="https://web.imbi.uni-heidelberg.de/prior/" class="external-link">here</a>
for details</p></dd>


<dt>a</dt>
<dd><p>lower boundary for the truncation of the <a href="https://web.imbi.uni-heidelberg.de/prior/" class="external-link">prior distribution</a></p></dd>


<dt>b</dt>
<dd><p>upper boundary for the truncation of the <a href="https://web.imbi.uni-heidelberg.de/prior/" class="external-link">prior distribution</a></p></dd>


<dt>n2min</dt>
<dd><p>minimal total sample size for phase II; must be an even number</p></dd>


<dt>n2max</dt>
<dd><p>maximal total sample size for phase II, must be an even number</p></dd>


<dt>stepn2</dt>
<dd><p>step size for the optimization over n2; must be an even number</p></dd>


<dt>kappamin</dt>
<dd><p>minimal threshold value kappa for the go/no-go decision rule</p></dd>


<dt>kappamax</dt>
<dd><p>maximal threshold value  kappa for the go/no-go decision rule</p></dd>


<dt>stepkappa</dt>
<dd><p>step size for the optimization over the threshold value kappa</p></dd>


<dt>alpha</dt>
<dd><p>significance level</p></dd>


<dt>beta</dt>
<dd><p>type II error rate; i.e. <code>1 - beta</code> is the power for calculation of the sample size for phase III</p></dd>


<dt>c2</dt>
<dd><p>variable per-patient cost for phase II in 10^5 $</p></dd>


<dt>c3</dt>
<dd><p>variable per-patient cost for phase III in 10^5 $</p></dd>


<dt>c02</dt>
<dd><p>fixed cost for phase II in 10^5 $</p></dd>


<dt>c03</dt>
<dd><p>fixed cost for phase III in 10^5 $</p></dd>


<dt>K</dt>
<dd><p>constraint on the costs of the program, default: Inf, e.g. no constraint</p></dd>


<dt>N</dt>
<dd><p>constraint on the total expected sample size of the program, default: Inf, e.g. no constraint</p></dd>


<dt>S</dt>
<dd><p>constraint on the expected probability of a successful program, default: -Inf, e.g. no constraint</p></dd>


<dt>steps1</dt>
<dd><p>lower boundary for effect size category "small", default: 0</p></dd>


<dt>stepm1</dt>
<dd><p>lower boundary for effect size category "medium" = upper boundary for effect size category "small" default: 0.5</p></dd>


<dt>stepl1</dt>
<dd><p>lower boundary for effect size category "large" = upper boundary for effect size category "medium", default: 0.8</p></dd>


<dt>b1</dt>
<dd><p>expected gain for effect size category "small" in 10^5 $</p></dd>


<dt>b2</dt>
<dd><p>expected gain for effect size category "medium" in 10^5 $</p></dd>


<dt>b3</dt>
<dd><p>expected gain for effect size category "large" in 10^5 $</p></dd>


<dt>gamma</dt>
<dd><p>to model different populations in phase II and III choose <code>gamma != 0</code>, default: 0, see
<a href="https://web.imbi.uni-heidelberg.de/prior/" class="external-link">here</a>
for details</p></dd>


<dt>fixed</dt>
<dd><p>choose if true treatment effects are fixed or following a prior distribution, if TRUE <code>Delta1</code> is used as fixed effect</p></dd>


<dt>skipII</dt>
<dd><p>choose if skipping phase II is an option, default: FALSE;
if TRUE, the program calculates the expected utility for the case when phase
II is skipped and compares it to the situation when phase II is not skipped.
The results are then returned as a two-row data frame, <code>res[1, ]</code>
being the results when including phase II and <code>res[2, ]</code> when skipping phase II.</p></dd>


<dt>num_cl</dt>
<dd><p>number of clusters used for parallel computing, default: 1</p></dd>

</dl></div>
    <div class="section level2">
    <h2 id="value">Value<a class="anchor" aria-label="anchor" href="#value"></a></h2>
    

<p>The output of the function <code>optimal_normal</code> is a data.frame containing the optimization results:</p><dl><dt>u</dt>
<dd><p>maximal expected utility under the optimization constraints, i.e. the expected utility of the optimal sample size and threshold value</p></dd>

<dt>Kappa</dt>
<dd><p>optimal threshold value for the decision rule to go to phase III</p></dd>

<dt>n2</dt>
<dd><p>total sample size for phase II</p></dd>

<dt>n3</dt>
<dd><p>total sample size for phase III; rounded to the next even natural number</p></dd>

<dt>n</dt>
<dd><p>total sample size in the program; n = n2 + n3</p></dd>

<dt>K</dt>
<dd><p>maximal costs of the program</p></dd>

<dt>pgo</dt>
<dd><p>probability to go to phase III</p></dd>

<dt>sProg</dt>
<dd><p>probability of a successful program</p></dd>

<dt>sProg1</dt>
<dd><p>probability of a successful program with "small" treatment effect in phase III</p></dd>

<dt>sProg2</dt>
<dd><p>probability of a successful program with "medium" treatment effect in phase III</p></dd>

<dt>sProg3</dt>
<dd><p>probability of a successful program with "large" treatment effect in phase III</p></dd>

<dt>K2</dt>
<dd><p>expected costs for phase II</p></dd>

<dt>K3</dt>
<dd><p>expected costs for phase III</p></dd>


</dl><p>and further input parameters.</p>


<p>Taking <code>cat(comment())</code> of the data.frame object lists the used optimization sequences, start and finish date of the optimization procedure.</p>
    </div>
    <div class="section level2">
    <h2 id="references">References<a class="anchor" aria-label="anchor" href="#references"></a></h2>
    <p>Cohen, J. (1988). Statistical power analysis for the behavioral sciences.</p>
    </div>

    <div class="section level2">
    <h2 id="ref-examples">Examples<a class="anchor" aria-label="anchor" href="#ref-examples"></a></h2>
    <div class="sourceCode"><pre class="sourceCode r"><code><span class="r-in"><span><span class="co"># Activate progress bar (optional)</span></span></span>
<span class="r-in"><span><span class="kw">if</span> <span class="op">(</span><span class="cn">FALSE</span><span class="op">)</span> <span class="fu">progressr</span><span class="fu">::</span><span class="fu"><a href="https://progressr.futureverse.org/reference/handlers.html" class="external-link">handlers</a></span><span class="op">(</span>global <span class="op">=</span> <span class="cn">TRUE</span><span class="op">)</span></span></span>
<span class="r-in"><span><span class="co"># Optimize</span></span></span>
<span class="r-in"><span><span class="co"># \donttest{</span></span></span>
<span class="r-in"><span><span class="fu">optimal_normal</span><span class="op">(</span>w<span class="op">=</span><span class="fl">0.3</span>,                       <span class="co"># define parameters for prior</span></span></span>
<span class="r-in"><span>  Delta1 <span class="op">=</span> <span class="fl">0.375</span>, Delta2 <span class="op">=</span> <span class="fl">0.625</span>, in1<span class="op">=</span><span class="fl">300</span>, in2<span class="op">=</span><span class="fl">600</span>,  <span class="co"># (https://web.imbi.uni-heidelberg.de/prior/)</span></span></span>
<span class="r-in"><span>  a <span class="op">=</span> <span class="fl">0.25</span>, b <span class="op">=</span> <span class="fl">0.75</span>,</span></span>
<span class="r-in"><span>  n2min <span class="op">=</span> <span class="fl">20</span>, n2max <span class="op">=</span> <span class="fl">100</span>, stepn2 <span class="op">=</span> <span class="fl">4</span>,               <span class="co"># define optimization set for n2</span></span></span>
<span class="r-in"><span>  kappamin <span class="op">=</span> <span class="fl">0.02</span>, kappamax <span class="op">=</span> <span class="fl">0.2</span>, stepkappa <span class="op">=</span> <span class="fl">0.02</span>, <span class="co"># define optimization set for kappa</span></span></span>
<span class="r-in"><span>  alpha <span class="op">=</span> <span class="fl">0.05</span>, beta <span class="op">=</span> <span class="fl">0.1</span>,                          <span class="co"># drug development planning parameters</span></span></span>
<span class="r-in"><span>  c2 <span class="op">=</span> <span class="fl">0.675</span>, c3 <span class="op">=</span> <span class="fl">0.72</span>, c02 <span class="op">=</span> <span class="fl">15</span>, c03 <span class="op">=</span> <span class="fl">20</span>,         <span class="co"># fixed/variable costs for phase II/III</span></span></span>
<span class="r-in"><span>  K <span class="op">=</span> <span class="cn">Inf</span>, N <span class="op">=</span> <span class="cn">Inf</span>, S <span class="op">=</span> <span class="op">-</span><span class="cn">Inf</span>,                        <span class="co"># set constraints</span></span></span>
<span class="r-in"><span>  steps1 <span class="op">=</span> <span class="fl">0</span>,                                        <span class="co"># define lower boundary for "small"</span></span></span>
<span class="r-in"><span>  stepm1 <span class="op">=</span> <span class="fl">0.5</span>,                                      <span class="co"># "medium"</span></span></span>
<span class="r-in"><span>  stepl1 <span class="op">=</span> <span class="fl">0.8</span>,                                      <span class="co"># and "large" effect size categories</span></span></span>
<span class="r-in"><span>  b1 <span class="op">=</span> <span class="fl">3000</span>, b2 <span class="op">=</span> <span class="fl">8000</span>, b3 <span class="op">=</span> <span class="fl">10000</span>,                  <span class="co"># benefit for each effect size category</span></span></span>
<span class="r-in"><span>  gamma <span class="op">=</span> <span class="fl">0</span>,                                         <span class="co"># population structures in phase II/III</span></span></span>
<span class="r-in"><span>  fixed <span class="op">=</span> <span class="cn">FALSE</span>,                                     <span class="co"># true treatment effects are fixed/random</span></span></span>
<span class="r-in"><span>  skipII <span class="op">=</span> <span class="cn">FALSE</span>,                                    <span class="co"># skipping phase II</span></span></span>
<span class="r-in"><span>  num_cl <span class="op">=</span> <span class="fl">1</span><span class="op">)</span>                                        <span class="co"># number of cores for parallelized computing</span></span></span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Optimization result:</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  Utility: 2272.13</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  Sample size:</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>    phase II: 100, phase III: 350, total: 450</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  Probability to go to phase III: 0.94</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  Total cost:</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>    phase II: 82, phase III: 271, cost constraint: Inf</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  Fixed cost:</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>    phase II: 15, phase III: 20</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  Variable cost per patient:</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>    phase II: 0.675, phase III: 0.72</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  Effect size categories (expected gains):</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   small: 0 (3000), medium: 0.5 (8000), large: 0.8 (10000)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  Success probability: 0.78</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  Success probability by effect size:</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>    small: 0.73, medium: 0.05, large: 0</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  Significance level: 0.05</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  Targeted power: 0.9</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  Decision rule threshold: 0.08 [Kappa] </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  Parameters of the prior distribution: </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>    Delta1: 0.375, Delta2: 0.625, in1: 300, in2: 600,</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>    a: 0.25, b: 0.75, w: 0.3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  Treatment effect offset between phase II and III: 0 [gamma] </span>
<span class="r-in"><span><span class="co"># }</span></span></span>
</code></pre></div>
    </div>
  </main><aside class="col-md-3"><nav id="toc"><h2>On this page</h2>
    </nav></aside></div>


    <footer><div class="pkgdown-footer-left">
  <p></p><p>Developed by Stella Erdmann, Johannes Cepicka, Marietta Kirchner, Meinhard Kieser, Lukas D. Sauer.</p>
</div>

<div class="pkgdown-footer-right">
  <p></p><p>Site built with <a href="https://pkgdown.r-lib.org/" class="external-link">pkgdown</a> 2.0.7.</p>
</div>

    </footer></div>

  

  

  </body></html>

